GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Total Assets

Biomerica (Biomerica) Total Assets : $10.34 Mil (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Total Assets?

Biomerica's Total Assets for the quarter that ended in Feb. 2024 was $10.34 Mil.

During the past 12 months, Biomerica's average Total Assets Growth Rate was 3.20% per year. During the past 3 years, the average Total Assets Growth Rate was -18.10% per year. During the past 5 years, the average Total Assets Growth Rate was 3.60% per year. During the past 10 years, the average Total Assets Growth Rate was 4.10% per year.

During the past 13 years, Biomerica's highest 3-Year average Total Assets Growth Rate was 86.20%. The lowest was -22.80%. And the median was 1.20%.

Total Assets is connected with ROA %. Biomerica's annualized ROA % for the quarter that ended in Feb. 2024 was -69.20%. Total Assets is also linked to Revenue through Asset Turnover. Biomerica's Asset Turnover for the quarter that ended in Feb. 2024 was 0.09.


Biomerica Total Assets Historical Data

The historical data trend for Biomerica's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Total Assets Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.25 17.26 11.82 11.37 14.45

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.21 14.45 13.22 11.83 10.34

Biomerica Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Biomerica's Total Assets for the fiscal year that ended in May. 2023 is calculated as

Total Assets=Total Equity (A: May. 2023 )+Total Liabilities (A: May. 2023 )
=11.724+2.73
=14.45

Biomerica's Total Assets for the quarter that ended in Feb. 2024 is calculated as

Total Assets=Total Equity (Q: Feb. 2024 )+Total Liabilities (Q: Feb. 2024 )
=7.808+2.534
=10.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) Total Assets Explanation

Total Assets is connected with ROA %.

Biomerica's annualized ROA % for the quarter that ended in Feb. 2024 is

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=-7.672/( (11.831+10.342)/ 2 )
=-7.672/11.0865
=-69.20 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Biomerica's Asset Turnover for the quarter that ended in Feb. 2024 is

Asset Turnover
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=1.017/( (11.831+10.342)/ 2 )
=1.017/11.0865
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Biomerica Total Assets Related Terms

Thank you for viewing the detailed overview of Biomerica's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663